NCT05631899View on ClinicalTrials.gov

CAR-DC Vaccine and ICIs in Local Advanced/Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 3, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
Solid Tumor, AdultEphA2 OverexpressionKRAS G12VKRAS G12CKRAS G12D
Interventions
BIOLOGICAL

KRAS-EphA-2-CAR-DC

5\~10 × 10\^6 CAR-DCs per dose will be administered by intravenous injection.

DRUG

Abraxane

Intravenous abraxane 125 mg/m\^2/day on day-5.

DRUG

Cyclophosphamide

Intravenous cyclophosphamide 300 mg/m\^2/day on day -4.

DRUG

Anti-PD-1 antibody

Intravenous anti-PD-1 antibody 200 mg/day.

DRUG

Anti-CTLA4 Monoclonal Antibody

Intravenous anti-CTLA4 antibody 1 mg/kg/day

Trial Locations (1)

100853

RECRUITING

Biotherapeutic Department of Chinsese PLA Gereral Hospital, Beijing

All Listed Sponsors
collaborator

Zhejiang University

OTHER

lead

Chinese PLA General Hospital

OTHER